cui1,cui2,relation,name1,name2,type1,type2,weight,predicate
C0000608,C0150312,TREATS,6-aminocaproic acid,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0001047,C0232807,TREATS,acetylcysteine,Decreased renal function,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0001047,C0442797,TREATS,acetylcysteine,Decreasing,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0001047,C4055506,TREATS,acetylcysteine,Accumulation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0001655,C0150312,TREATS,corticotropin,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002059,C1704202,TREATS,Alkaline Phosphatase,Aspermia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002191,C0241863,TREATS,alpha 1-antitrypsin,diabetic,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002191,C0332509,TREATS,alpha 1-antitrypsin,Increased size (finding),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002199,C0150312,TREATS,Interferon-alpha,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002199,C0221198,TREATS,Interferon-alpha,Lesion,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0002199,C0237677,TREATS,Interferon-alpha,insensitivity,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002199,C0332155,TREATS,Interferon-alpha,Did not receive therapy or drug for,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0002199,C0424470,TREATS,Interferon-alpha,Undressed,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002199,C0439663,TREATS,Interferon-alpha,Infected,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0002199,C0562577,TREATS,Interferon-alpha,Mocking,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002199,C1444662,TREATS,Interferon-alpha,Discontinued,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002199,C1545588,TREATS,Interferon-alpha,Protection,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002199,C1836348,TREATS,Interferon-alpha,Severe disorder,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002199,C4321237,TREATS,Interferon-alpha,High Level,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002199,C4699604,TREATS,Interferon-alpha,<12 months,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0002199,C5202576,TREATS,Interferon-alpha,Biochemical Diagnosis,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002520,C0150312,TREATS,Amino Acids,Present,aapp,fndg,4,TREATS_AAPPtrtsFNDG
C0002520,C0205160,TREATS,Amino Acids,Negative,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002520,C0332461,TREATS,Amino Acids,Plaque (lesion),aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0002520,C0332575,TREATS,Amino Acids,Redness,aapp,fndg,20,TREATS_AAPPtrtsFNDG
C0002520,C0424589,TREATS,Amino Acids,Vitality,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002520,C0427184,TREATS,Amino Acids,No incoordination,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002520,C0439663,TREATS,Amino Acids,Infected,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002520,C0442797,TREATS,Amino Acids,Decreasing,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002520,C0557351,TREATS,Amino Acids,Employed,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002520,C0679218,TREATS,Amino Acids,Resting state,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002520,C0750484,TREATS,Amino Acids,Confirmation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002520,C1444656,TREATS,Amino Acids,Indicated,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002520,C1519255,TREATS,Amino Acids,Serious Adverse Event,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002520,C1865782,TREATS,Amino Acids,CEREBELLAR DEGENERATION-RELATED AUTOANTIGEN 3,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002520,C1953367,TREATS,Amino Acids,Reference sequence,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0002520,C3715215,TREATS,Amino Acids,S1,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002520,C4321237,TREATS,Amino Acids,High Level,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002520,C4699181,TREATS,Amino Acids,Lattice,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0002525,C0392209,TREATS,"Amino Acids, Essential",Nutritional status,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003006,C0020649,TREATS,Angiotensin I,Hypotension,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003009,C0150312,TREATS,angiotensin II,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003009,C5231182,TREATS,angiotensin II,Normal lung,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003018,C0086565,TREATS,Angiotensins,Liver Dysfunction,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003134,C0392209,TREATS,Anserine,Nutritional status,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0003126,TREATS,Antibodies,Anosmia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0009940,TREATS,Antibodies,Convalescence,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0010038,TREATS,Antibodies,Corneal Opacity,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0015663,TREATS,Antibodies,Fasting,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0033213,TREATS,Antibodies,Problem,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0003241,C0035648,TREATS,Antibodies,risk factors,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0085393,TREATS,Antibodies,Immunocompromised Host,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0003241,C0149744,TREATS,Antibodies,Oral lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0150312,TREATS,Antibodies,Present,aapp,fndg,39,TREATS_AAPPtrtsFNDG
C0003241,C0152031,TREATS,Antibodies,Joint swelling,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0205160,TREATS,Antibodies,Negative,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0003241,C0221198,TREATS,Antibodies,Lesion,aapp,fndg,5,TREATS_AAPPtrtsFNDG
C0003241,C0231221,TREATS,Antibodies,Asymptomatic,aapp,fndg,7,TREATS_AAPPtrtsFNDG
C0003241,C0231337,TREATS,Antibodies,Senility,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0239984,TREATS,Antibodies,Increased circulating IgA level,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0003241,C0241863,TREATS,Antibodies,diabetic,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0003241,C0277545,TREATS,Antibodies,Disease type AND/OR category unknown,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0332149,TREATS,Antibodies,Possible,aapp,fndg,5,TREATS_AAPPtrtsFNDG
C0003241,C0332155,TREATS,Antibodies,Did not receive therapy or drug for,aapp,fndg,4,TREATS_AAPPtrtsFNDG
C0003241,C0332575,TREATS,Antibodies,Redness,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0003241,C0392209,TREATS,Antibodies,Nutritional status,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0418624,TREATS,Antibodies,Nonadministration of necessary drug or medicine,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0422837,TREATS,Antibodies,Neurological observations,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0003241,C0424576,TREATS,Antibodies,Fit and well,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0003241,C0425945,TREATS,Antibodies,Prolonged menses,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0425946,TREATS,Antibodies,Short menstrual periods,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0428642,TREATS,Antibodies,Pulmonary artery pressure,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0436343,TREATS,Antibodies,Symptom mild,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0439662,TREATS,Antibodies,Immune,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0003241,C0439663,TREATS,Antibodies,Infected,aapp,fndg,13,TREATS_AAPPtrtsFNDG
C0003241,C0442726,TREATS,Antibodies,Detected (finding),aapp,fndg,4,TREATS_AAPPtrtsFNDG
C0003241,C0442749,TREATS,Antibodies,6/5,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0442753,TREATS,Antibodies,Distance vision 6/18,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0442760,TREATS,Antibodies,3/9,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0456128,TREATS,Antibodies,Term infant (finding),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0460089,TREATS,Antibodies,Duration of gestation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0544452,TREATS,Antibodies,Disease remission,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0562577,TREATS,Antibodies,Mocking,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0566701,TREATS,Antibodies,Placenta infected,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0577059,TREATS,Antibodies,Liver normal,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0003241,C0577305,TREATS,Antibodies,Multiple lesions,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0578757,TREATS,Antibodies,Good neonatal condition at birth,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0586144,TREATS,Antibodies,Monitoring status,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0600140,TREATS,Antibodies,Does run (finding),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0600457,TREATS,Antibodies,Gravidity,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0679246,TREATS,Antibodies,advanced disease,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0683314,TREATS,Antibodies,personal health,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0686750,TREATS,Antibodies,Well adult,aapp,fndg,5,TREATS_AAPPtrtsFNDG
C0003241,C0728725,TREATS,Antibodies,Low pH,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0003241,C0746619,TREATS,Antibodies,monoclonal,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0003241,C0748604,TREATS,Antibodies,seizure new onset,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C0750479,TREATS,Antibodies,blank,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0003241,C0750484,TREATS,Antibodies,Confirmation,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0003241,C1116171,TREATS,Antibodies,Vaccinated at,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C1171159,TREATS,Antibodies,Fertility risk,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C1395724,TREATS,Antibodies,Donor Lymphocytes,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C1519789,TREATS,Antibodies,Unexpected Adverse Event,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C1545588,TREATS,Antibodies,Protection,aapp,fndg,26,TREATS_AAPPtrtsFNDG
C0003241,C1546905,TREATS,Antibodies,Tissue diagnosis,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C1690939,TREATS,Antibodies,20/25,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C1704632,TREATS,Antibodies,Disease Response,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C1832406,TREATS,Antibodies,Severe clinical course,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C1836348,TREATS,Antibodies,Severe disorder,aapp,fndg,4,TREATS_AAPPtrtsFNDG
C0003241,C1859430,TREATS,Antibodies,Life-threatening infections,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C1865782,TREATS,Antibodies,CEREBELLAR DEGENERATION-RELATED AUTOANTIGEN 3,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0003241,C2985294,TREATS,Antibodies,Fourth Stage of Labor,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C3149149,TREATS,Antibodies,COLOSTRUM SECRETION,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C3151529,TREATS,Antibodies,Lethal,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C3272283,TREATS,Antibodies,American College of Cardiology/American Heart Association Lesion Complexity Score C,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0003241,C3273245,TREATS,Antibodies,Acute Rejection,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0003241,C3540840,TREATS,Antibodies,Sign or Symptom,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C3668831,TREATS,Antibodies,Lactation established in non-human animal,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C3715215,TREATS,Antibodies,S1,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C3841839,TREATS,Antibodies,Person 5,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C3843057,TREATS,Antibodies,Second half,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C3843058,TREATS,Antibodies,First half,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C3843708,TREATS,Antibodies,29+,aapp,fndg,4,TREATS_AAPPtrtsFNDG
C0003241,C3845919,TREATS,Antibodies,Absorptive,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C3887628,TREATS,Antibodies,Circulating immune complexes,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C4035626,TREATS,Antibodies,3 times,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C4050466,TREATS,Antibodies,Borg Category-Ratio 10 Perceived Exertion Score 5,aapp,fndg,6,TREATS_AAPPtrtsFNDG
C0003241,C4055506,TREATS,Antibodies,Accumulation,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0003241,C4288557,TREATS,Antibodies,One Activity Hour,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0003241,C4289767,TREATS,Antibodies,Colonization,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C4314158,TREATS,Antibodies,Inflammatory colitis,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C4321237,TREATS,Antibodies,High Level,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C4321351,TREATS,Antibodies,Low Level,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0003241,C4531406,TREATS,Antibodies,Continuous flow,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C4699566,TREATS,Antibodies,Past infection,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C4699604,TREATS,Antibodies,<12 months,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C4700073,TREATS,Antibodies,Perinuclear,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003241,C4747995,TREATS,Antibodies,Nasal secretions,aapp,fndg,7,TREATS_AAPPtrtsFNDG
C0003313,C0221198,TREATS,Immune complex,Lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003403,C2825142,TREATS,Antipain,Experimental Result,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003438,C0015663,TREATS,antithrombin III,Fasting,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003442,C0020649,TREATS,"lymphocyte immune globulin, anti-thymocyte globulin",Hypotension,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003442,C0039231,TREATS,"lymphocyte immune globulin, anti-thymocyte globulin",Tachycardia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003442,C0497365,TREATS,"lymphocyte immune globulin, anti-thymocyte globulin",Generalized rash,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003442,C1836348,TREATS,"lymphocyte immune globulin, anti-thymocyte globulin",Severe disorder,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003442,C3273245,TREATS,"lymphocyte immune globulin, anti-thymocyte globulin",Acute Rejection,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003641,C0150312,TREATS,aprotinin,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003765,C0332516,TREATS,arginine,Symmetrical,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003993,C0150312,TREATS,asparaginase,Present,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0003993,C0240604,TREATS,asparaginase,birth control pill use,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003993,C0442797,TREATS,asparaginase,Decreasing,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0004609,C0026826,TREATS,baclofen,Muscle Hypertonia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0004609,C4553743,TREATS,baclofen,"Spasticity, CTCAE",aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0005789,C0020672,TREATS,Blood Coagulation Factor,"Hypothermia, natural",aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0005789,C0853225,TREATS,Blood Coagulation Factor,INR Increased,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0006050,C0427149,TREATS,botulinum toxin type A,"Gait, Drop Foot",aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0006055,C0037301,TREATS,Botulinum Toxins,Skin Wrinkling,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0006100,C4747995,TREATS,Bradykinin,Nasal secretions,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0006217,C0015663,TREATS,bromelains,Fasting,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0006217,C0150312,TREATS,bromelains,Present,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0006938,C0150312,TREATS,captopril,Present,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0006938,C0205161,TREATS,captopril,Abnormal,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0006938,C0860761,TREATS,captopril,pH high,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0006938,C3887644,TREATS,captopril,Inflammatory infiltrate,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0007258,C1704202,TREATS,carnitine,Aspermia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0007267,C0344353,TREATS,carnosine,Vegan diet,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0007332,C0239987,TREATS,caseins,Deceased IgG,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0008742,C4699378,TREATS,chymotrypsin,High expression,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0009325,C0221198,TREATS,collagen,Lesion,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0009325,C0241158,TREATS,collagen,Scar Tissue,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0009325,C1444662,TREATS,collagen,Discontinued,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0010286,C0392209,TREATS,creatine,Nutritional status,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0010592,C0035648,TREATS,cyclosporine,risk factors,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0010592,C0085393,TREATS,cyclosporine,Immunocompromised Host,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0010592,C0332149,TREATS,cyclosporine,Possible,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0010592,C0600457,TREATS,cyclosporine,Gravidity,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0010592,C0679246,TREATS,cyclosporine,advanced disease,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0010592,C1262477,TREATS,cyclosporine,Weight decreased,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0010592,C3273245,TREATS,cyclosporine,Acute Rejection,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0011522,C0429706,TREATS,deoxyribonucleases,Forced expiratory volume in 1 second finding,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0011701,C1299586,TREATS,desmopressin,Has difficulty doing (qualifier value),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0012020,C0038435,TREATS,Diazooxonorleucine,Stress,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0012020,C0150312,TREATS,Diazooxonorleucine,Present,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0012020,C0439662,TREATS,Diazooxonorleucine,Immune,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0012020,C0562389,TREATS,Diazooxonorleucine,Victim of child abuse,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0012020,C1832073,TREATS,Diazooxonorleucine,Handling,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0012020,C3842953,TREATS,Diazooxonorleucine,> 24 hrs,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0012020,C4698719,TREATS,Diazooxonorleucine,Confirmed case,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0014025,C0332155,TREATS,enalapril,Did not receive therapy or drug for,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0014025,C1882086,TREATS,enalapril,New York Heart Association Class III,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0014027,C0086565,TREATS,enalaprilat,Liver Dysfunction,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0014822,C0206160,TREATS,Erythropoietin,Reticulocytosis,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0014822,C1821244,TREATS,Erythropoietin,Normal development,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015506,C0332149,TREATS,factor VIII,Possible,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015506,C0683525,TREATS,factor VIII,treatment options,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015506,C1963076,TREATS,factor VIII,"Platelets, CTCAE",aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015520,C0150312,TREATS,Factor Xa,Present,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0015528,C0150312,TREATS,factor XIII,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015879,C0014745,TREATS,Ferritin,Palmar erythema,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015879,C0150312,TREATS,Ferritin,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015879,C0221198,TREATS,Ferritin,Lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015879,C0241863,TREATS,Ferritin,diabetic,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015879,C0574941,TREATS,Ferritin,Inflamed joint,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015879,C1545588,TREATS,Ferritin,Protection,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0015879,C1836348,TREATS,Ferritin,Severe disorder,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015879,C3806166,TREATS,Ferritin,Poor outcome,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0015879,C4534547,TREATS,Ferritin,Initial day,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015980,C0032972,TREATS,interferon-beta,Pregnancy Outcome,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015980,C0332149,TREATS,interferon-beta,Possible,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015980,C0439663,TREATS,interferon-beta,Infected,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015980,C3272903,TREATS,interferon-beta,Overall Response,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015980,C4050466,TREATS,interferon-beta,Borg Category-Ratio 10 Perceived Exertion Score 5,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015982,C0150312,TREATS,Fibrin,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015982,C0332575,TREATS,Fibrin,Redness,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0016006,C0184511,TREATS,fibrinogen,Improved,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0016006,C0241863,TREATS,fibrinogen,diabetic,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0016006,C0424561,TREATS,fibrinogen,Bleeds profusely,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0016006,C1457868,TREATS,fibrinogen,Worse,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0016006,C1836348,TREATS,fibrinogen,Severe disorder,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0016006,C3843309,TREATS,fibrinogen,1 time,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0016006,C4050466,TREATS,fibrinogen,Borg Category-Ratio 10 Perceived Exertion Score 5,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0016006,C4086268,TREATS,fibrinogen,Exacerbation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0016006,C4329792,TREATS,fibrinogen,Eosinophilic Globules,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0017237,C0332461,TREATS,gelatin,Plaque (lesion),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0017687,C0241863,TREATS,glucagon,diabetic,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0017687,C4018909,TREATS,glucagon,Overdose,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0017797,C0021294,TREATS,glutamine,"Infant, Premature",aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0017797,C0150312,TREATS,glutamine,Present,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0017797,C1832073,TREATS,glutamine,Handling,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0017817,C0150312,TREATS,glutathione,Present,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0017817,C0337664,TREATS,glutathione,Smoker,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0017817,C0337672,TREATS,glutathione,Non-smoker,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0017817,C1545588,TREATS,glutathione,Protection,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0017817,C4018909,TREATS,glutathione,Overdose,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0017817,C4230430,TREATS,glutathione,Inflammatory lung disease,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0017817,C4321237,TREATS,glutathione,High Level,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0017817,C5231182,TREATS,glutathione,Normal lung,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0017890,C0150312,TREATS,glycine,Present,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0017890,C0686750,TREATS,glycine,Well adult,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0017976,C0033213,TREATS,Glycoside Hydrolases,Problem,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0017976,C0332149,TREATS,Glycoside Hydrolases,Possible,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0018061,C1626404,TREATS,Gonadotropins,Post-pubertal,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0018061,C1628325,TREATS,Gonadotropins,Pre-pubertal,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0018061,C3540840,TREATS,Gonadotropins,Sign or Symptom,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0018909,C1545588,TREATS,Hemagglutinin,Protection,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0019167,C1444656,TREATS,Hepatitis B e Antigens,Indicated,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0019602,C0332575,TREATS,histidine,Redness,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0019602,C0427184,TREATS,histidine,No incoordination,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0019602,C0728725,TREATS,histidine,Low pH,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0019602,C1519789,TREATS,histidine,Unexpected Adverse Event,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0019602,C4699368,TREATS,histidine,Wild-type strain,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0020197,C4055506,TREATS,hyaluronidase,Accumulation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0020197,C4740633,TREATS,hyaluronidase,Enzymatic digestion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0020388,C0332155,TREATS,hydroxyproline,Did not receive therapy or drug for,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0020388,C0392209,TREATS,hydroxyproline,Nutritional status,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0020388,C4054143,TREATS,hydroxyproline,Pulmonary Compliance,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0020731,C0600457,TREATS,Pertussis Toxin,Gravidity,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0020852,C0562577,TREATS,immunoglobulin G,Mocking,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0020852,C0750484,TREATS,immunoglobulin G,Confirmation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0020960,C0150312,TREATS,Immune Sera,Present,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0020960,C0205557,TREATS,Immune Sera,False Positive,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0020960,C0439662,TREATS,Immune Sera,Immune,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0020960,C0442726,TREATS,Immune Sera,Detected (finding),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0020960,C0542243,TREATS,Immune Sera,toxic reaction (non-specific),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0020960,C0562577,TREATS,Immune Sera,Mocking,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0020960,C0750479,TREATS,Immune Sera,blank,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0020960,C0750484,TREATS,Immune Sera,Confirmation,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0020960,C1262477,TREATS,Immune Sera,Weight decreased,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0020960,C1290905,TREATS,Immune Sera,Discrepancy (finding),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0020960,C1545588,TREATS,Immune Sera,Protection,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0020960,C1859430,TREATS,Immune Sera,Life-threatening infections,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0021641,C0017747,TREATS,Insulin,Increased glucose level,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021641,C0017979,TREATS,Insulin,Glycosuria,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021641,C0020461,TREATS,Insulin,Hyperkalemia,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0021641,C0150312,TREATS,Insulin,Present,aapp,fndg,10,TREATS_AAPPtrtsFNDG
C0021641,C0231221,TREATS,Insulin,Asymptomatic,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021641,C0239979,TREATS,Insulin,"HYPERGLYCEMIA, SEVERE",aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021641,C0241863,TREATS,Insulin,diabetic,aapp,fndg,7,TREATS_AAPPtrtsFNDG
C0021641,C0332149,TREATS,Insulin,Possible,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021641,C0442757,TREATS,Insulin,3/4,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021641,C0580545,TREATS,Insulin,Blood glucose normal,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021641,C0595877,TREATS,Insulin,Blood glucose increased,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021641,C0750484,TREATS,Insulin,Confirmation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021641,C0861023,TREATS,Insulin,insulin low,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021641,C1328773,TREATS,Insulin,Ineffective tissue perfusion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021641,C1708385,TREATS,Insulin,Hospitalization Required,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021641,C1881358,TREATS,Insulin,Large Mass,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021641,C3272283,TREATS,Insulin,American College of Cardiology/American Heart Association Lesion Complexity Score C,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021641,C4534363,TREATS,Insulin,At home,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021641,C4554418,TREATS,Insulin,Parallel,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021740,C0150312,TREATS,Recombinant Interferon-gamma,Present,aapp,fndg,4,TREATS_AAPPtrtsFNDG
C0021740,C0221198,TREATS,Recombinant Interferon-gamma,Lesion,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0021740,C0439663,TREATS,Recombinant Interferon-gamma,Infected,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0021740,C0458075,TREATS,Recombinant Interferon-gamma,Well baby,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021740,C0748025,TREATS,Recombinant Interferon-gamma,Low protein level,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021740,C4313322,TREATS,Recombinant Interferon-gamma,Alveolar damage,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021740,C4321237,TREATS,Recombinant Interferon-gamma,High Level,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021743,C0436345,TREATS,Interferon Type I,Symptom severe,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021743,C4747995,TREATS,Interferon Type I,Nasal secretions,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0021753,C0150312,TREATS,"interleukin-1, beta",Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021753,C0333361,TREATS,"interleukin-1, beta",Acute inflammation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021755,C0686750,TREATS,Interleukin-1,Well adult,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021755,C3807248,TREATS,Interleukin-1,Hyperinflammatory disorder,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021756,C0150312,TREATS,Interleukin-2,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021756,C3807248,TREATS,Interleukin-2,Hyperinflammatory disorder,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021758,C0221198,TREATS,interleukin-4,Lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021760,C0150312,TREATS,interleukin-6,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021760,C0333361,TREATS,interleukin-6,Acute inflammation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021760,C3807248,TREATS,interleukin-6,Hyperinflammatory disorder,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021761,C0015663,TREATS,interleukin-7,Fasting,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021761,C4050466,TREATS,interleukin-7,Borg Category-Ratio 10 Perceived Exertion Score 5,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0022192,C0184512,TREATS,isoleucine,Stabilized (qualifier value),aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0022192,C1113650,TREATS,isoleucine,brain morphology,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0022192,C4018909,TREATS,isoleucine,Overdose,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0022474,C4747995,TREATS,Kallidin,Nasal secretions,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0023401,C0150312,TREATS,leucine,Present,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0023401,C1881707,TREATS,leucine,Material Degradation,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0023570,C0221198,TREATS,levodopa,Lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0023570,C0311394,TREATS,levodopa,Difficulty walking,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0023570,C1843921,TREATS,levodopa,Postural instability,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0023570,C2674101,TREATS,levodopa,Autonomic symptoms,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0023607,C3843058,TREATS,luteinizing hormone,First half,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0023610,C0085639,TREATS,gonadorelin,Falls,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0023610,C1832073,TREATS,gonadorelin,Handling,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0023764,C0021294,TREATS,lipase,"Infant, Premature",aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0023764,C0231221,TREATS,lipase,Asymptomatic,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0023764,C1836348,TREATS,lipase,Severe disorder,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0023764,C3841253,TREATS,lipase,Reusable,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0024337,C0150312,TREATS,lysine,Present,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0024337,C0427184,TREATS,lysine,No incoordination,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0024337,C0439662,TREATS,lysine,Immune,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0024337,C4699368,TREATS,lysine,Wild-type strain,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0025646,C0150312,TREATS,methionine,Present,aapp,fndg,6,TREATS_AAPPtrtsFNDG
C0025646,C0332155,TREATS,methionine,Did not receive therapy or drug for,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0025646,C0439663,TREATS,methionine,Infected,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0025646,C3843058,TREATS,methionine,First half,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0025646,C4288085,TREATS,methionine,Two to Five Activity Hours,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0025741,C0021294,TREATS,methyldopa,"Infant, Premature",aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0026794,C0150312,TREATS,muramidase,Present,aapp,fndg,4,TREATS_AAPPtrtsFNDG
C0026794,C0522567,TREATS,muramidase,Mild inflammation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0026794,C4018909,TREATS,muramidase,Overdose,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0026794,C4747995,TREATS,muramidase,Nasal secretions,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0027597,C0150312,TREATS,Zinostatin,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0027597,C0240341,TREATS,Zinostatin,Micrographia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0027803,C1545588,TREATS,Neuraminidase,Protection,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0028833,C0020621,TREATS,octreotide,Hypokalemia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0028833,C0425945,TREATS,octreotide,Prolonged menses,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0028833,C0428977,TREATS,octreotide,Bradycardia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0030095,C0012154,TREATS,oxytocin,Diestrus,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0030095,C0020505,TREATS,oxytocin,Hyperphagia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0030095,C0025597,TREATS,oxytocin,Metestrus,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0030095,C0043094,TREATS,oxytocin,Weight Gain,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0030095,C0150312,TREATS,oxytocin,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0030095,C2712122,TREATS,oxytocin,Normal blood pressure,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0030346,C1833692,TREATS,papain,"OTITIS MEDIA, SUSCEPTIBILITY TO (finding)",aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0030520,C1821244,TREATS,parathyroid hormone,Normal development,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0030817,C0033687,TREATS,penicillamine,Proteinuria,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0030817,C0035648,TREATS,penicillamine,risk factors,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0030817,C0277854,TREATS,penicillamine,dyspneic,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0030817,C0577053,TREATS,penicillamine,Lesion of liver,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0031453,C1883041,TREATS,phenylalanine,Device Slipped,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0031634,C4050466,TREATS,Phosphocreatine,Borg Category-Ratio 10 Perceived Exertion Score 5,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0032140,C0221198,TREATS,Plasminogen,Lesion,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0032140,C0700292,TREATS,Plasminogen,Hypoxemia,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0032143,C0020649,TREATS,alteplase,Hypotension,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0032143,C0150312,TREATS,alteplase,Present,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0032143,C0241863,TREATS,alteplase,diabetic,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0032143,C0332155,TREATS,alteplase,Did not receive therapy or drug for,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0032143,C0422837,TREATS,alteplase,Neurological observations,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0032143,C0442757,TREATS,alteplase,3/4,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0032143,C0442797,TREATS,alteplase,Decreasing,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0032143,C0521654,TREATS,alteplase,Neurologic Deficits,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0032143,C0562577,TREATS,alteplase,Mocking,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0032143,C0700292,TREATS,alteplase,Hypoxemia,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0032143,C0848894,TREATS,alteplase,normal patient,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0032143,C1298827,TREATS,alteplase,Severe thrombus,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0032143,C1299448,TREATS,alteplase,Patient ventilated,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0032143,C1998827,TREATS,alteplase,Respiratory Status,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0032143,C2959885,TREATS,alteplase,Microthrombus,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0032143,C3536594,TREATS,alteplase,Suspected cerebrovascular accident,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0032143,C4050466,TREATS,alteplase,Borg Category-Ratio 10 Perceived Exertion Score 5,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0032143,C4698447,TREATS,alteplase,Patient age,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0032144,C0574941,TREATS,Plasminogen Activator,Inflamed joint,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0032200,C0686750,TREATS,Platelet-Derived Growth Factor,Well adult,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0033371,C0012154,TREATS,prolactin,Diestrus,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0033382,C0332575,TREATS,proline,Redness,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0033602,C0150312,TREATS,protamine sulfate (USP),Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0033621,C0683954,TREATS,protein C,research results,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0034862,C0007294,TREATS,"Vaccines, Recombinant",Genetic Carriers,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0034862,C0150312,TREATS,"Vaccines, Recombinant",Present,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0034862,C0439663,TREATS,"Vaccines, Recombinant",Infected,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0034862,C1545588,TREATS,"Vaccines, Recombinant",Protection,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0034862,C2945640,TREATS,"Vaccines, Recombinant",compromise,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0035031,C0012154,TREATS,Relaxin,Diestrus,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0036002,C0150312,TREATS,S-adenosylmethionine,Present,aapp,fndg,5,TREATS_AAPPtrtsFNDG
C0036002,C0332575,TREATS,S-adenosylmethionine,Redness,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0036720,C0332575,TREATS,serine,Redness,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0036720,C1519789,TREATS,serine,Unexpected Adverse Event,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0037511,C0085393,TREATS,sodium glutamate,Immunocompromised Host,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0037659,C0015663,TREATS,somatostatin,Fasting,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0037659,C0150312,TREATS,somatostatin,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0037659,C0232341,TREATS,somatostatin,Increased vascular flow,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0038838,C0232970,TREATS,superoxide dismutase,Postmenopausal state,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0039350,C0241863,TREATS,taurine,diabetic,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0039617,C0332461,TREATS,tetanus toxin,Plaque (lesion),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0040005,C0332575,TREATS,threonine,Redness,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0040005,C1519789,TREATS,threonine,Unexpected Adverse Event,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0040018,C0150312,TREATS,thrombin,Present,aapp,fndg,5,TREATS_AAPPtrtsFNDG
C0040018,C1963076,TREATS,thrombin,"Platelets, CTCAE",aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0040498,C0150312,TREATS,Tosylphenylalanyl Chloromethyl Ketone,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0040691,C5231182,TREATS,Transforming Growth Factors,Normal lung,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041014,C0150312,TREATS,liothyronine,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041236,C0086439,TREATS,trypsin,Hypokinesia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041236,C0150312,TREATS,trypsin,Present,aapp,fndg,28,TREATS_AAPPtrtsFNDG
C0041236,C0332149,TREATS,trypsin,Possible,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041236,C0332155,TREATS,trypsin,Did not receive therapy or drug for,aapp,fndg,6,TREATS_AAPPtrtsFNDG
C0041236,C0425945,TREATS,trypsin,Prolonged menses,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041236,C0456913,TREATS,trypsin,Cold medium,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041236,C0562577,TREATS,trypsin,Mocking,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0041236,C0728725,TREATS,trypsin,Low pH,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0041236,C1444656,TREATS,trypsin,Indicated,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041236,C3842675,TREATS,trypsin,Day 3,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041236,C4321237,TREATS,trypsin,High Level,aapp,fndg,4,TREATS_AAPPtrtsFNDG
C0041242,C0150312,TREATS,Trypsin Inhibitors,Present,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0041242,C0332575,TREATS,Trypsin Inhibitors,Redness,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041249,C0038435,TREATS,tryptophan,Stress,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041249,C0150312,TREATS,tryptophan,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041249,C0332575,TREATS,tryptophan,Redness,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041249,C1865782,TREATS,tryptophan,CEREBELLAR DEGENERATION-RELATED AUTOANTIGEN 3,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041368,C0439663,TREATS,Tumor Necrosis Factors,Infected,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041485,C0332575,TREATS,tyrosine,Redness,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041485,C1865782,TREATS,tyrosine,CEREBELLAR DEGENERATION-RELATED AUTOANTIGEN 3,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041485,C1953367,TREATS,tyrosine,Reference sequence,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042071,C0574941,TREATS,urokinase,Inflamed joint,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C0015663,TREATS,Vaccines,Fasting,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0042210,C0024032,TREATS,Vaccines,Low Birth Weights,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C0030544,TREATS,Vaccines,PARENTAL CONCERNS,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C0033213,TREATS,Vaccines,Problem,aapp,fndg,4,TREATS_AAPPtrtsFNDG
C0042210,C0038435,TREATS,Vaccines,Stress,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0042210,C0085393,TREATS,Vaccines,Immunocompromised Host,aapp,fndg,15,TREATS_AAPPtrtsFNDG
C0042210,C0085639,TREATS,Vaccines,Falls,aapp,fndg,5,TREATS_AAPPtrtsFNDG
C0042210,C0150312,TREATS,Vaccines,Present,aapp,fndg,29,TREATS_AAPPtrtsFNDG
C0042210,C0156543,TREATS,Vaccines,Unspecified Abortion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C0184511,TREATS,Vaccines,Improved,aapp,fndg,4,TREATS_AAPPtrtsFNDG
C0042210,C0221198,TREATS,Vaccines,Lesion,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0042210,C0231224,TREATS,Vaccines,Crisis,aapp,fndg,10,TREATS_AAPPtrtsFNDG
C0042210,C0231337,TREATS,Vaccines,Senility,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0042210,C0231519,TREATS,Vaccines,Gegenhalten,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C0237849,TREATS,Vaccines,Peeling of skin,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C0239998,TREATS,Vaccines,Recurrent infections,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C0262926,TREATS,Vaccines,Medical History,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0042210,C0332149,TREATS,Vaccines,Possible,aapp,fndg,10,TREATS_AAPPtrtsFNDG
C0042210,C0332155,TREATS,Vaccines,Did not receive therapy or drug for,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C0332461,TREATS,Vaccines,Plaque (lesion),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C0332575,TREATS,Vaccines,Redness,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0042210,C0392209,TREATS,Vaccines,Nutritional status,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0042210,C0424576,TREATS,Vaccines,Fit and well,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C0425946,TREATS,Vaccines,Short menstrual periods,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0042210,C0427184,TREATS,Vaccines,No incoordination,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0042210,C0439662,TREATS,Vaccines,Immune,aapp,fndg,4,TREATS_AAPPtrtsFNDG
C0042210,C0439663,TREATS,Vaccines,Infected,aapp,fndg,10,TREATS_AAPPtrtsFNDG
C0042210,C0442797,TREATS,Vaccines,Decreasing,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0042210,C0476442,TREATS,Vaccines,High antibody titer,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C0518609,TREATS,Vaccines,Consideration,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C0521874,TREATS,Vaccines,Victim of neglect (finding),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C0557722,TREATS,Vaccines,High risk environment,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C0558187,TREATS,Vaccines,Lactation established (finding),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C0562577,TREATS,Vaccines,Mocking,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0042210,C0595998,TREATS,Vaccines,Household composition,aapp,fndg,5,TREATS_AAPPtrtsFNDG
C0042210,C0596013,TREATS,Vaccines,Does stand,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C0600140,TREATS,Vaccines,Does run (finding),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C0600457,TREATS,Vaccines,Gravidity,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0042210,C0679246,TREATS,Vaccines,advanced disease,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0042210,C0686744,TREATS,Vaccines,Well child,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C0686747,TREATS,Vaccines,Well adolescent,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C0686750,TREATS,Vaccines,Well adult,aapp,fndg,21,TREATS_AAPPtrtsFNDG
C0042210,C0750558,TREATS,Vaccines,Unlikely,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C1116171,TREATS,Vaccines,Vaccinated at,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0042210,C1275743,TREATS,Vaccines,Co-morbid conditions,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C1299586,TREATS,Vaccines,Has difficulty doing (qualifier value),aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0042210,C1318963,TREATS,Vaccines,Readiness,aapp,fndg,12,TREATS_AAPPtrtsFNDG
C0042210,C1519789,TREATS,Vaccines,Unexpected Adverse Event,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C1533098,TREATS,Vaccines,Panleukopenia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C1545588,TREATS,Vaccines,Protection,aapp,fndg,50,TREATS_AAPPtrtsFNDG
C0042210,C1558931,TREATS,Vaccines,"Flu-Like Syndrome, CTCAE",aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C1709157,TREATS,Vaccines,Negative Surgical Margin,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C1836348,TREATS,Vaccines,Severe disorder,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C1838994,TREATS,Vaccines,Rapid onset,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C1859430,TREATS,Vaccines,Life-threatening infections,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C1879646,TREATS,Vaccines,Affected Area,aapp,fndg,4,TREATS_AAPPtrtsFNDG
C0042210,C2676468,TREATS,Vaccines,"SARCOIDOSIS, SUSCEPTIBILITY TO, 2",aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C2945640,TREATS,Vaccines,compromise,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C2986560,TREATS,Vaccines,Best Overall Response,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C3151529,TREATS,Vaccines,Lethal,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C3272283,TREATS,Vaccines,American College of Cardiology/American Heart Association Lesion Complexity Score C,aapp,fndg,4,TREATS_AAPPtrtsFNDG
C0042210,C3540840,TREATS,Vaccines,Sign or Symptom,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C3714738,TREATS,Vaccines,Compliance,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C3806166,TREATS,Vaccines,Poor outcome,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C3816499,TREATS,Vaccines,Pathogenic,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C3840593,TREATS,Vaccines,Trial 1,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C3840775,TREATS,Vaccines,Anticipated,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C3841750,TREATS,Vaccines,Mass gathering,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C3842677,TREATS,Vaccines,Very hard,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C3842777,TREATS,Vaccines,Trial 2,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C3843057,TREATS,Vaccines,Second half,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0042210,C3843087,TREATS,Vaccines,One thing,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0042210,C3843645,TREATS,Vaccines,1-10,aapp,fndg,4,TREATS_AAPPtrtsFNDG
C0042210,C3843647,TREATS,Vaccines,> 2 years,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0042210,C3846676,TREATS,Vaccines,Confidential,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C3887485,TREATS,Vaccines,"MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 1",aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C4036061,TREATS,Vaccines,Drug-drug,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C4050466,TREATS,Vaccines,Borg Category-Ratio 10 Perceived Exertion Score 5,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C4055223,TREATS,Vaccines,Clinical Response,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C4055506,TREATS,Vaccines,Accumulation,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0042210,C4264314,TREATS,Vaccines,Childhood diseases,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C4289767,TREATS,Vaccines,Colonization,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C4554418,TREATS,Vaccines,Parallel,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C4699181,TREATS,Vaccines,Lattice,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C4699368,TREATS,Vaccines,Wild-type strain,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0042210,C4699604,TREATS,Vaccines,<12 months,aapp,fndg,5,TREATS_AAPPtrtsFNDG
C0042210,C4699618,TREATS,Vaccines,>65 years,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0042210,C4745084,TREATS,Vaccines,Medical Condition,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C4747995,TREATS,Vaccines,Nasal secretions,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042210,C5204818,TREATS,Vaccines,Global Response,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042413,C0020649,TREATS,Vasopressins,Hypotension,aapp,fndg,5,TREATS_AAPPtrtsFNDG
C0042413,C0150312,TREATS,Vasopressins,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042971,C0241863,TREATS,von Willebrand factor,diabetic,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0043396,C0150312,TREATS,Yellow fever virus,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0043396,C3840862,TREATS,Yellow fever virus,75+ years,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0051846,C0205400,TREATS,angiopeptin,Thickened,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0052897,C0683337,TREATS,bactericidal permeability increasing protein,Late disease stage,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0053355,C0332155,TREATS,ubenimex,Did not receive therapy or drug for,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0054534,C4021734,TREATS,calpastatin,Abnormality of mitochondrial metabolism,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0057002,C1836348,TREATS,cytomegalovirus immune globulin,Severe disorder,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0057002,C4554665,TREATS,cytomegalovirus immune globulin,"Cytomegalovirus Infection Reactivation, CTCAE",aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0057256,C0439662,TREATS,Defensins,Immune,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0057256,C0679250,TREATS,Defensins,Disease Outcome,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0057256,C2673622,TREATS,Defensins,Mucosal lesions,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0061472,C0150312,TREATS,glutamic acid,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0061472,C0332575,TREATS,glutamic acid,Redness,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0062525,C0239998,TREATS,hepatitis B immune globulin,Recurrent infections,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0062525,C1709795,TREATS,hepatitis B immune globulin,Quantitative Result,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0062525,C3272281,TREATS,hepatitis B immune globulin,American College of Cardiology/American Heart Association Lesion Complexity Score A,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0063717,C0679250,TREATS,Interleukin 6 Receptor,Disease Outcome,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0064858,C0150312,TREATS,leupeptin,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0064858,C0424589,TREATS,leupeptin,Vitality,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0064858,C4055506,TREATS,leupeptin,Accumulation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0065374,C0427184,TREATS,lisinopril,No incoordination,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0073870,C4055506,TREATS,S-ethyl glutathione,Accumulation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0075029,C2826940,TREATS,spleen fibrinolytic proteinase (human),Physical Examination Location,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0075029,C4699604,TREATS,spleen fibrinolytic proteinase (human),<12 months,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0077906,C0221198,TREATS,urinastatin,Lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0078080,C0150312,TREATS,"vasopressin, 1-(1-mercaptocyclohexaneacetic acid)-2-(O- methyl-L-tyrosine)-8-L-arginine-",Present,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0079189,C1545588,TREATS,cytokine,Protection,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0079189,C4086268,TREATS,cytokine,Exacerbation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0079189,C4534547,TREATS,cytokine,Initial day,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0079459,C0686750,TREATS,Granulocyte Colony-Stimulating Factor,Well adult,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0079460,C0686750,TREATS,Granulocyte-Macrophage Colony-Stimulating Factor,Well adult,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0079633,C0439663,TREATS,interleukin-8,Infected,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0079633,C0686750,TREATS,interleukin-8,Well adult,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0079633,C3807248,TREATS,interleukin-8,Hyperinflammatory disorder,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0079633,C3843265,TREATS,interleukin-8,Line 2,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0080225,C0150312,TREATS,thymopentin,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0083031,C1514815,TREATS,interleukin-11,Refractory Disease,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0083031,C4747995,TREATS,interleukin-11,Nasal secretions,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0083183,C0232459,TREATS,lactase,Abnormal digestive tract function,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0083220,C0085639,TREATS,deslorelin,Falls,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0084178,C0150312,TREATS,prohibitin,Present,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0085295,C0686750,TREATS,interleukin-10,Well adult,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0015663,TREATS,"immunoglobulins, intravenous",Fasting,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0085297,C0021294,TREATS,"immunoglobulins, intravenous","Infant, Premature",aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0027854,TREATS,"immunoglobulins, intravenous",Neurologic Manifestations,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0035648,TREATS,"immunoglobulins, intravenous",risk factors,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0085297,C0085393,TREATS,"immunoglobulins, intravenous",Immunocompromised Host,aapp,fndg,5,TREATS_AAPPtrtsFNDG
C0085297,C0150312,TREATS,"immunoglobulins, intravenous",Present,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0085297,C0205160,TREATS,"immunoglobulins, intravenous",Negative,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0085297,C0221198,TREATS,"immunoglobulins, intravenous",Lesion,aapp,fndg,4,TREATS_AAPPtrtsFNDG
C0085297,C0231224,TREATS,"immunoglobulins, intravenous",Crisis,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0085297,C0232915,TREATS,"immunoglobulins, intravenous",No visible estrus,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0085297,C0239998,TREATS,"immunoglobulins, intravenous",Recurrent infections,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0241863,TREATS,"immunoglobulins, intravenous",diabetic,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0277786,TREATS,"immunoglobulins, intravenous",Chief complaint (finding),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0277797,TREATS,"immunoglobulins, intravenous",Apyrexial,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0278060,TREATS,"immunoglobulins, intravenous",Mental state,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0278252,TREATS,"immunoglobulins, intravenous",Prognosis bad,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0332149,TREATS,"immunoglobulins, intravenous",Possible,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0425710,TREATS,"immunoglobulins, intravenous",Peripheral perfusion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0436345,TREATS,"immunoglobulins, intravenous",Symptom severe,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0439662,TREATS,"immunoglobulins, intravenous",Immune,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0481667,TREATS,"immunoglobulins, intravenous",Live Birth,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0518609,TREATS,"immunoglobulins, intravenous",Consideration,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0683320,TREATS,"immunoglobulins, intravenous",unwellness,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0743630,TREATS,"immunoglobulins, intravenous",exacerbation acute,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0750394,TREATS,"immunoglobulins, intravenous",White blood cell count decreased,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0815189,TREATS,"immunoglobulins, intravenous",treatment need,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0920247,TREATS,"immunoglobulins, intravenous",Rubeola exposure,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C1263979,TREATS,"immunoglobulins, intravenous",Severe cytopenia,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0085297,C1457868,TREATS,"immunoglobulins, intravenous",Worse,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C1836348,TREATS,"immunoglobulins, intravenous",Severe disorder,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0085297,C1998827,TREATS,"immunoglobulins, intravenous",Respiratory Status,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C2826210,TREATS,"immunoglobulins, intravenous",Complete Recovery,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C2945640,TREATS,"immunoglobulins, intravenous",compromise,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0085297,C3272283,TREATS,"immunoglobulins, intravenous",American College of Cardiology/American Heart Association Lesion Complexity Score C,aapp,fndg,6,TREATS_AAPPtrtsFNDG
C0085297,C3274777,TREATS,"immunoglobulins, intravenous",Severely Abnormal Ventricular Ejection Fraction,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C3806482,TREATS,"immunoglobulins, intravenous",Recurrent respiratory infections,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0085297,C3830314,TREATS,"immunoglobulins, intravenous",Enhancing Lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C3843196,TREATS,"immunoglobulins, intravenous",3 to 5 days,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C3843647,TREATS,"immunoglobulins, intravenous",> 2 years,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C4050466,TREATS,"immunoglobulins, intravenous",Borg Category-Ratio 10 Perceived Exertion Score 5,aapp,fndg,4,TREATS_AAPPtrtsFNDG
C0085297,C4053862,TREATS,"immunoglobulins, intravenous",Virologic Response,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0085297,C4054987,TREATS,"immunoglobulins, intravenous",Favorable Response,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0085297,C4304283,TREATS,"immunoglobulins, intravenous",Refractory hypotension,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C4321237,TREATS,"immunoglobulins, intravenous",High Level,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C4321351,TREATS,"immunoglobulins, intravenous",Low Level,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C4699604,TREATS,"immunoglobulins, intravenous",<12 months,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085379,C0035648,TREATS,muromonab-CD3,risk factors,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085379,C0150312,TREATS,muromonab-CD3,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085379,C3280504,TREATS,muromonab-CD3,Crypt hyperplasia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085741,C0442797,TREATS,"Pancreatic Trypsin Secretory Inhibitor, Kazal",Decreasing,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0103306,C0020649,TREATS,angiotensin I (1-7),Hypotension,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0103306,C0150312,TREATS,angiotensin I (1-7),Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0103306,C0332149,TREATS,angiotensin I (1-7),Possible,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0103306,C0497247,TREATS,angiotensin I (1-7),Increase in blood pressure,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0103306,C0683314,TREATS,angiotensin I (1-7),personal health,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0123759,C0150312,TREATS,interleukin-12,Present,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0123759,C0332155,TREATS,interleukin-12,Did not receive therapy or drug for,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0123759,C0562577,TREATS,interleukin-12,Mocking,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0123759,C0574941,TREATS,interleukin-12,Inflamed joint,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0123759,C3807248,TREATS,interleukin-12,Hyperinflammatory disorder,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0123759,C3842673,TREATS,interleukin-12,Day 6,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0123759,C4321237,TREATS,interleukin-12,High Level,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0162745,C0150312,TREATS,collagenase,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0162745,C0154270,TREATS,collagenase,Localized adiposity,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0162745,C1833692,TREATS,collagenase,"OTITIS MEDIA, SUSCEPTIBILITY TO (finding)",aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0162745,C4740633,TREATS,collagenase,Enzymatic digestion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0164613,C0238983,TREATS,interferon alfacon-1,Chest deformity,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0164707,C1963076,TREATS,Tissue factor pathway inhibitor,"Platelets, CTCAE",aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0168273,C0232805,TREATS,bivalirudin,Normal renal function,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0169911,C0231162,TREATS,messenger protein,Normal general body function,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0169964,C0332149,TREATS,somatropin,Possible,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0172511,C0150312,TREATS,interferon-alpha 8,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0210630,C0038002,TREATS,filgrastim,Splenomegaly,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0210638,C0428648,TREATS,Alveofact,Inspired oxygen concentration,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0221138,C0150312,TREATS,Blood group antibody I,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0242275,C5231182,TREATS,epidermal growth factor,Normal lung,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0245109,C0027854,TREATS,anakinra,Neurologic Manifestations,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0245109,C0150312,TREATS,anakinra,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0245109,C0221198,TREATS,anakinra,Lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0245109,C0332155,TREATS,anakinra,Did not receive therapy or drug for,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0245109,C0439662,TREATS,anakinra,Immune,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0245109,C0686750,TREATS,anakinra,Well adult,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0245109,C0700292,TREATS,anakinra,Hypoxemia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0245109,C1260922,TREATS,anakinra,Abnormal breathing,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0245109,C1836348,TREATS,anakinra,Severe disorder,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0245109,C1998827,TREATS,anakinra,Respiratory Status,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0245109,C3276087,TREATS,anakinra,Elevated inflammatory markers,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0245109,C3807248,TREATS,anakinra,Hyperinflammatory disorder,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0245109,C3845888,TREATS,anakinra,Known allergy,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0245109,C3890735,TREATS,anakinra,Complete Response with Incomplete Platelet Recovery,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0245109,C4050466,TREATS,anakinra,Borg Category-Ratio 10 Perceived Exertion Score 5,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0245109,C4747995,TREATS,anakinra,Nasal secretions,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0254610,C0574941,TREATS,Interleukin-15,Inflamed joint,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0282554,C4534547,TREATS,chemokine,Initial day,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0301503,C4050466,TREATS,"rabies immune globulin, human",Borg Category-Ratio 10 Perceived Exertion Score 5,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0304925,C0150312,TREATS,"albumin human, USP",Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0305052,C0150312,TREATS,Gamma globulin serum,Present,aapp,fndg,7,TREATS_AAPPtrtsFNDG
C0305052,C0332575,TREATS,Gamma globulin serum,Redness,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0305052,C0439662,TREATS,Gamma globulin serum,Immune,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0305052,C0439663,TREATS,Gamma globulin serum,Infected,aapp,fndg,5,TREATS_AAPPtrtsFNDG
C0305052,C0562577,TREATS,Gamma globulin serum,Mocking,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0305052,C1514463,TREATS,Gamma globulin serum,Prior Therapy,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0305052,C1545588,TREATS,Gamma globulin serum,Protection,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0308550,C0221198,TREATS,BRSV,Lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0308550,C0436345,TREATS,BRSV,Symptom severe,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0308550,C4747995,TREATS,BRSV,Nasal secretions,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0310756,C0241334,TREATS,Parainfluenza 3 vaccine,TEMPERATE CLIMATE,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0310969,C0150312,TREATS,Escherichia coli antibody,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0358321,C0442797,TREATS,Immune Globulin (Human),Decreasing,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0358321,C0581126,TREATS,Immune Globulin (Human),Severe asthma,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0358321,C1514815,TREATS,Immune Globulin (Human),Refractory Disease,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0358321,C1861874,TREATS,Immune Globulin (Human),Severe atopic dermatitis,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0358321,C2826244,TREATS,Immune Globulin (Human),Life Threatening,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0358321,C4266464,TREATS,Immune Globulin (Human),Gated,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0359180,C0150312,TREATS,Albumin solution,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0360722,C4055506,TREATS,Enzyme agent,Accumulation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0376659,C1545588,TREATS,Cancer Vaccines,Protection,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0377091,C0150312,TREATS,Glycopeptidase F,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0379135,C0743150,TREATS,becaplermin,diabetic ulcer,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0383429,C0332149,TREATS,alemtuzumab,Possible,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0383429,C0582147,TREATS,alemtuzumab,At risk of infection,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0383429,C1836348,TREATS,alemtuzumab,Severe disorder,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0383429,C2963400,TREATS,alemtuzumab,Cell phase,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0383429,C3272283,TREATS,alemtuzumab,American College of Cardiology/American Heart Association Lesion Complexity Score C,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0383429,C3273245,TREATS,alemtuzumab,Acute Rejection,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0383779,C0562577,TREATS,benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone,Mocking,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0383779,C1550518,TREATS,benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone,incapable,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0385112,C4055506,TREATS,HLA-DR13 antigen,Accumulation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0388014,C0021294,TREATS,Respigam,"Infant, Premature",aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0391001,C1444662,TREATS,peginterferon alfa-2a,Discontinued,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0393022,C0264939,TREATS,rituximab,Systemic Vasculitis,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0393022,C0277786,TREATS,rituximab,Chief complaint (finding),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0393022,C0332149,TREATS,rituximab,Possible,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0393022,C0544452,TREATS,rituximab,Disease remission,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0393022,C0743630,TREATS,rituximab,exacerbation acute,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0393022,C0814128,TREATS,rituximab,sustained remission,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0393022,C1333400,TREATS,rituximab,Gadolinium-Enhancing Lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0393022,C1514815,TREATS,rituximab,Refractory Disease,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0393022,C1521726,TREATS,rituximab,partial response,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0393022,C1560152,TREATS,rituximab,"Grade 4 Vasculitis, CTCAE",aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0393022,C1839972,TREATS,rituximab,Increased circulating IgM level,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0393022,C1962917,TREATS,rituximab,High grade (lymphoma grade) (finding),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0393022,C3272281,TREATS,rituximab,American College of Cardiology/American Heart Association Lesion Complexity Score A,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0393022,C3272283,TREATS,rituximab,American College of Cardiology/American Heart Association Lesion Complexity Score C,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0393022,C3272903,TREATS,rituximab,Overall Response,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0393022,C4014164,TREATS,rituximab,Lymphoproliferation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0393022,C4055223,TREATS,rituximab,Clinical Response,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0443469,C0333574,TREATS,pancreatic lipase,Fatty deposition,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0443619,C4329792,TREATS,Antichymotrypsin,Eosinophilic Globules,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0457610,C0427184,TREATS,Measles-rubella vaccine (live),No incoordination,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0457610,C0679218,TREATS,Measles-rubella vaccine (live),Resting state,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0537439,C0439663,TREATS,enfuvirtide,Infected,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0537894,C1836348,TREATS,caspofungin,Severe disorder,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0538777,C4321237,TREATS,ancestim,High Level,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0594372,C0750484,TREATS,Avonex,Confirmation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0597357,C5231182,TREATS,receptor,Normal lung,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0597418,C1545588,TREATS,Rotavirus Vaccines,Protection,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0650607,C0231221,TREATS,Basal insulin,Asymptomatic,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0650607,C0239979,TREATS,Basal insulin,"HYPERGLYCEMIA, SEVERE",aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0650607,C2826244,TREATS,Basal insulin,Life Threatening,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0664336,C0574941,TREATS,survivin,Inflamed joint,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0666743,C0021294,TREATS,infliximab,"Infant, Premature",aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0666743,C0150312,TREATS,infliximab,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0666743,C0749075,TREATS,infliximab,STRUCTURAL Abnormalities,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0666743,C1444662,TREATS,infliximab,Discontinued,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0666743,C1859543,TREATS,infliximab,Severe colitis,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0666743,C3842672,TREATS,infliximab,Day 7,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0672596,C0021294,TREATS,palivizumab,"Infant, Premature",aapp,fndg,4,TREATS_AAPPtrtsFNDG
C0672596,C0419437,TREATS,palivizumab,High risk infant,aapp,fndg,12,TREATS_AAPPtrtsFNDG
C0672596,C3272283,TREATS,palivizumab,American College of Cardiology/American Heart Association Lesion Complexity Score C,aapp,fndg,8,TREATS_AAPPtrtsFNDG
C0677829,C0743150,TREATS,palifermin,diabetic ulcer,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0700607,C2826244,TREATS,digoxin antibodies Fab fragments,Life Threatening,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0700607,C4018909,TREATS,digoxin antibodies Fab fragments,Overdose,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0701459,C3540840,TREATS,Lupron,Sign or Symptom,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0702053,C4551754,TREATS,RhoGAM,RhD negative,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0717758,C0150312,TREATS,etanercept,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0717758,C0221198,TREATS,etanercept,Lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0717758,C1444662,TREATS,etanercept,Discontinued,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0724532,C1709770,TREATS,"antithrombin III, human",Pulmonary Dysfunction,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0724601,C0241863,TREATS,"insulin, regular, pork",diabetic,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0728747,C0150312,TREATS,trastuzumab,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0732165,C4699604,TREATS,Somatostatin analog,<12 months,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0751599,C0332509,TREATS,Recombinant Interferon Beta,Increased size (finding),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0751599,C0349790,TREATS,Recombinant Interferon Beta,Exacerbation of asthma,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0751599,C4086268,TREATS,Recombinant Interferon Beta,Exacerbation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0754923,C1135241,TREATS,sinapultide,Weeks pregnant,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0795657,C5233569,TREATS,"alpha 1-proteinase inhibitor, human",Oxygen dependence,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0795677,C0150312,TREATS,"von Willebrand factor, human",Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0796392,C0332149,TREATS,bevacizumab,Possible,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0796392,C0442797,TREATS,bevacizumab,Decreasing,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0796392,C1317600,TREATS,bevacizumab,patient symptoms,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0796392,C2825972,TREATS,bevacizumab,Cant,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0796392,C4050466,TREATS,bevacizumab,Borg Category-Ratio 10 Perceived Exertion Score 5,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0796392,C4699604,TREATS,bevacizumab,<12 months,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0887943,C1545588,TREATS,alpha-Defensins,Protection,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0911901,C0150312,TREATS,benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0920330,C1444662,TREATS,Pancreatic enzyme,Discontinued,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0966225,C0349790,TREATS,omalizumab,Exacerbation of asthma,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0966225,C0581126,TREATS,omalizumab,Severe asthma,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0966225,C4050466,TREATS,omalizumab,Borg Category-Ratio 10 Perceived Exertion Score 5,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0966225,C4086268,TREATS,omalizumab,Exacerbation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0969324,C0349790,TREATS,mepolizumab,Exacerbation of asthma,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0969324,C0581124,TREATS,mepolizumab,Mild asthma,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0969324,C0581126,TREATS,mepolizumab,Severe asthma,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0969324,C4086268,TREATS,mepolizumab,Exacerbation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0982327,C0221198,TREATS,PEGINTERFERON,Lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0982327,C4699604,TREATS,PEGINTERFERON,<12 months,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0995188,C0205160,TREATS,cetuximab,Negative,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0995188,C0278252,TREATS,cetuximab,Prognosis bad,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0995188,C0332149,TREATS,cetuximab,Possible,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C1135662,C0700292,TREATS,dornase alfa,Hypoxemia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1135662,C1299448,TREATS,dornase alfa,Patient ventilated,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1136247,C0012154,TREATS,Pregnant Mare Serum Gonadotropins,Diestrus,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1138321,C0235896,TREATS,glutoxim,Pulmonary Infiltrate,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1170000,C3272283,TREATS,drotrecogin alfa,American College of Cardiology/American Heart Association Lesion Complexity Score C,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1171255,C0184511,TREATS,Humira,Improved,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1172734,C1855010,TREATS,natalizumab,Progressive leukoencephalopathy,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1256770,C0686750,TREATS,Vascular Endothelial Growth Factors,Well adult,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1413765,C0150312,TREATS,CSPG5 gene,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1418198,C2826940,TREATS,OTP gene,Physical Examination Location,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1418544,C4329792,TREATS,SERPINA1 gene,Eosinophilic Globules,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1422064,C0332575,TREATS,ACE2 gene,Redness,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1422064,C4321237,TREATS,ACE2 gene,High Level,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1448177,C0150312,TREATS,"TNF protein, human",Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1448177,C0221198,TREATS,"TNF protein, human",Lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1448177,C0333361,TREATS,"TNF protein, human",Acute inflammation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1449159,C0686750,TREATS,"CCL2 protein, human",Well adult,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1504688,C0679250,TREATS,"IL1RN protein, human",Disease Outcome,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1504688,C1299586,TREATS,"IL1RN protein, human",Has difficulty doing (qualifier value),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1509509,C0600457,TREATS,Filamentous haemagglutinin adsorbed,Gravidity,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1512511,C0221198,TREATS,Human Papilloma Virus Vaccine,Lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1515370,C1262477,TREATS,Recombinant Fas Ligand,Weight decreased,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1515370,C3476546,TREATS,Recombinant Fas Ligand,Symptoms score,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1515370,C4313322,TREATS,Recombinant Fas Ligand,Alveolar damage,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1517683,C4484175,TREATS,L-Selenomethionine,Growth Phase,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1522537,C0332155,TREATS,Recombinant Interferon,Did not receive therapy or drug for,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1522537,C3476546,TREATS,Recombinant Interferon,Symptoms score,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1522712,C0150312,TREATS,Recombinant Interferon-alpha Inducible Protein 10,Present,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C1522712,C0337664,TREATS,Recombinant Interferon-alpha Inducible Protein 10,Smoker,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1522712,C0429706,TREATS,Recombinant Interferon-alpha Inducible Protein 10,Forced expiratory volume in 1 second finding,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1522712,C0439663,TREATS,Recombinant Interferon-alpha Inducible Protein 10,Infected,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C1522712,C0686750,TREATS,Recombinant Interferon-alpha Inducible Protein 10,Well adult,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C1522712,C1836348,TREATS,Recombinant Interferon-alpha Inducible Protein 10,Severe disorder,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1522712,C3843265,TREATS,Recombinant Interferon-alpha Inducible Protein 10,Line 2,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1522712,C4050466,TREATS,Recombinant Interferon-alpha Inducible Protein 10,Borg Category-Ratio 10 Perceived Exertion Score 5,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C1524094,C0518609,TREATS,Recombinant Cytokines,Consideration,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1527233,C0150312,TREATS,Recombinant Immune Globulin,Present,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C1527233,C0439662,TREATS,Recombinant Immune Globulin,Immune,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1527233,C0439663,TREATS,Recombinant Immune Globulin,Infected,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1527233,C0521874,TREATS,Recombinant Immune Globulin,Victim of neglect (finding),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1541483,C0027854,TREATS,eculizumab,Neurologic Manifestations,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1541483,C0683954,TREATS,eculizumab,research results,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1541483,C2826210,TREATS,eculizumab,Complete Recovery,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1566537,C3714738,TREATS,ranibizumab,Compliance,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C0015663,TREATS,tocilizumab,Fasting,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C0019209,TREATS,tocilizumab,Hepatomegaly,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C0029053,TREATS,tocilizumab,Decreased translucency,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C1609165,C0033213,TREATS,tocilizumab,Problem,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C0150312,TREATS,tocilizumab,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C0184511,TREATS,tocilizumab,Improved,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C0221198,TREATS,tocilizumab,Lesion,aapp,fndg,6,TREATS_AAPPtrtsFNDG
C1609165,C0231221,TREATS,tocilizumab,Asymptomatic,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C0241863,TREATS,tocilizumab,diabetic,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C1609165,C0332149,TREATS,tocilizumab,Possible,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C1609165,C0424755,TREATS,tocilizumab,Fever symptoms (finding),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C0436345,TREATS,tocilizumab,Symptom severe,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C1609165,C0439662,TREATS,tocilizumab,Immune,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C0439663,TREATS,tocilizumab,Infected,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C0442797,TREATS,tocilizumab,Decreasing,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C0518609,TREATS,tocilizumab,Consideration,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C0522224,TREATS,tocilizumab,Paralysed,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C0544452,TREATS,tocilizumab,Disease remission,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C0600457,TREATS,tocilizumab,Gravidity,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C0700292,TREATS,tocilizumab,Hypoxemia,aapp,fndg,5,TREATS_AAPPtrtsFNDG
C1609165,C0743630,TREATS,tocilizumab,exacerbation acute,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C0750484,TREATS,tocilizumab,Confirmation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C1299448,TREATS,tocilizumab,Patient ventilated,aapp,fndg,5,TREATS_AAPPtrtsFNDG
C1609165,C1457868,TREATS,tocilizumab,Worse,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C1609165,C1836348,TREATS,tocilizumab,Severe disorder,aapp,fndg,17,TREATS_AAPPtrtsFNDG
C1609165,C1850165,TREATS,tocilizumab,Elevated IL6,aapp,fndg,11,TREATS_AAPPtrtsFNDG
C1609165,C1859543,TREATS,tocilizumab,Severe colitis,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C1998827,TREATS,tocilizumab,Respiratory Status,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C2826244,TREATS,tocilizumab,Life Threatening,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C3276087,TREATS,tocilizumab,Elevated inflammatory markers,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C3540840,TREATS,tocilizumab,Sign or Symptom,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C3811922,TREATS,tocilizumab,Liver transplant recipient,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C3842674,TREATS,tocilizumab,Day 5,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C3843398,TREATS,tocilizumab,15-19,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C3844126,TREATS,tocilizumab,Can Do Very Little,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C1609165,C3890735,TREATS,tocilizumab,Complete Response with Incomplete Platelet Recovery,aapp,fndg,9,TREATS_AAPPtrtsFNDG
C1609165,C4050466,TREATS,tocilizumab,Borg Category-Ratio 10 Perceived Exertion Score 5,aapp,fndg,31,TREATS_AAPPtrtsFNDG
C1609165,C4086268,TREATS,tocilizumab,Exacerbation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C4321237,TREATS,tocilizumab,High Level,aapp,fndg,6,TREATS_AAPPtrtsFNDG
C1609165,C4698386,TREATS,tocilizumab,Intubated,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C1609165,C4722602,TREATS,tocilizumab,Underlying,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609931,C1836348,TREATS,siltuximab,Severe disorder,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609931,C1850165,TREATS,siltuximab,Elevated IL6,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609931,C3890735,TREATS,siltuximab,Complete Response with Incomplete Platelet Recovery,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609931,C4050466,TREATS,siltuximab,Borg Category-Ratio 10 Perceived Exertion Score 5,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1619966,C4014164,TREATS,abatacept,Lymphoproliferation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1690432,C1444662,TREATS,denosumab,Discontinued,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1699239,C0686750,TREATS,"IL7 protein, human",Well adult,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1699801,C0686750,TREATS,"IL9 protein, human",Well adult,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1701084,C0150312,TREATS,"CD9 protein, human",Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1706044,C0150312,TREATS,PTPN11 wt Allele,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1707382,C4053862,TREATS,bavituximab,Virologic Response,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1723401,C3280118,TREATS,belimumab,Mild disorder,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1872203,C0683525,TREATS,pasireotide,treatment options,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1876229,C0439663,TREATS,telaprevir,Infected,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1882138,C5142828,TREATS,ocrelizumab,Full recovery,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2003387,C0085393,TREATS,DAS181,Immunocompromised Host,aapp,fndg,6,TREATS_AAPPtrtsFNDG
C2003387,C1836348,TREATS,DAS181,Severe disorder,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2003387,C3842674,TREATS,DAS181,Day 5,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2346819,C0516981,TREATS,tanezumab,Physical function,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2350701,C0686750,TREATS,Macrophage Inflammatory Protein-1,Well adult,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C2353893,C0581126,TREATS,golimumab,Severe asthma,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2608641,C0686750,TREATS,ACAM2000,Well adult,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2698127,C4055506,TREATS,Anti-CD25 Monoclonal Antibody,Accumulation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2713599,C0021294,TREATS,motavizumab,"Infant, Premature",aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2713599,C0085393,TREATS,motavizumab,Immunocompromised Host,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2713599,C0439663,TREATS,motavizumab,Infected,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2713599,C0686750,TREATS,motavizumab,Well adult,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2718773,C0086565,TREATS,canakinumab,Liver Dysfunction,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2718773,C1836348,TREATS,canakinumab,Severe disorder,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2718773,C3714738,TREATS,canakinumab,Compliance,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2718773,C3843647,TREATS,canakinumab,> 2 years,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2719767,C4745084,TREATS,onabotulinumtoxinA,Medical Condition,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2742502,C4013784,TREATS,ramucirumab,"Hypertension, severe",aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2742797,C1859543,TREATS,vedolizumab,Severe colitis,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2930113,C0150312,TREATS,incobotulinumtoxinA,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2930113,C0560046,TREATS,incobotulinumtoxinA,Unable to walk (finding),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2930113,C1262869,TREATS,incobotulinumtoxinA,Body position,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2930113,C3549934,TREATS,incobotulinumtoxinA,Equinus,aapp,fndg,5,TREATS_AAPPtrtsFNDG
C2930113,C4035885,TREATS,incobotulinumtoxinA,Ambulant,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2930113,C4699604,TREATS,incobotulinumtoxinA,<12 months,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2973446,C1444662,TREATS,brentuximab vedotin,Discontinued,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2981360,C4086268,TREATS,lebrikizumab,Exacerbation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2981360,C4321237,TREATS,lebrikizumab,High Level,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C2982078,C0581126,TREATS,benralizumab,Severe asthma,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C3179547,C4534363,TREATS,secukinumab,At home,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3181598,C0332575,TREATS,2F5 monoclonal antibody,Redness,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3272237,C4050466,TREATS,roactemra,Borg Category-Ratio 10 Perceived Exertion Score 5,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3491162,C4264438,TREATS,alirocumab,Compound heterozygous,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3537035,C4054479,TREATS,kinase inhibitor,Molecular Response,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3641657,C0231224,TREATS,Internalized-arginylglycylaspartic Acid Cyclic Peptide,Crisis,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3657270,C1517874,TREATS,nivolumab,Life Threatening Adverse Event,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3657270,C1834700,TREATS,nivolumab,Rapid disease progression,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3657270,C3272903,TREATS,nivolumab,Overall Response,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3657270,C4053982,TREATS,nivolumab,Subsequent Relapse,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3657282,C0020649,TREATS,alamandine,Hypotension,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3658706,C0745761,TREATS,pembrolizumab,Nodule of liver,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3658706,C3843647,TREATS,pembrolizumab,> 2 years,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3658706,C4054275,TREATS,pembrolizumab,PD-L1 Overexpression,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3660996,C0184511,TREATS,dupilumab,Improved,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3660996,C0581126,TREATS,dupilumab,Severe asthma,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C3660996,C4699158,TREATS,dupilumab,Increased risk,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3692257,C0686750,TREATS,Basic Fibroblast Growth Factor,Well adult,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3818725,C0150312,TREATS,"corticotropin, human",Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3849701,C0574941,TREATS,"interleukin 18 protein, human",Inflamed joint,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3849701,C3807248,TREATS,"interleukin 18 protein, human",Hyperinflammatory disorder,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3849701,C4321237,TREATS,"interleukin 18 protein, human",High Level,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3853839,C0439662,TREATS,blinatumomab,Immune,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3885145,C1836348,TREATS,sarilumab,Severe disorder,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3885145,C3846671,TREATS,sarilumab,Single Hospital,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3885145,C4050466,TREATS,sarilumab,Borg Category-Ratio 10 Perceived Exertion Score 5,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C4084937,C0085393,TREATS,Antimicrobial Peptide,Immunocompromised Host,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C4084937,C4086268,TREATS,Antimicrobial Peptide,Exacerbation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C4086595,C0436345,TREATS,Monalizumab,Symptom severe,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C4087043,C0701159,TREATS,Lenzilumab,Patient in hospital,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C4087043,C3272283,TREATS,Lenzilumab,American College of Cardiology/American Heart Association Lesion Complexity Score C,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C4087043,C4050466,TREATS,Lenzilumab,Borg Category-Ratio 10 Perceived Exertion Score 5,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C4277602,C0679250,TREATS,Butyrophilins,Disease Outcome,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C4309315,C0150312,TREATS,MI-0701,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C4520829,C0858603,TREATS,"Cholecystokinin, human",wave slowing,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C4550350,C1519255,TREATS,ravulizumab,Serious Adverse Event,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C4551622,C0150312,TREATS,T20 Peptide,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C4682406,C0332155,TREATS,Spartalizumab,Did not receive therapy or drug for,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C4727016,C1560209,TREATS,sutimlimab,"Hemolysis, CTCAE",aapp,fndg,1,TREATS_AAPPtrtsFNDG
C4730999,C5197672,TREATS,leronlimab,Symptom Exacerbation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C4733494,C1521726,TREATS,Naxitamab,partial response,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C5197773,C0439663,TREATS,Broadly Neutralizing Antibodies,Infected,aapp,fndg,1,TREATS_AAPPtrtsFNDG
